Published in Eur J Cancer on January 01, 1994
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09
Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun (2007) 1.82
Intraoperative molecular imaging can identify lung adenocarcinomas during pulmonary resection. J Thorac Cardiovasc Surg (2015) 1.48
Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro. Clin Exp Metastasis (1999) 1.46
Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res (2013) 1.28
Characterization of the human folate receptor alpha via novel antibody-based probes. Oncotarget (2011) 1.06
Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome. J Control Release (2010) 1.04
Reduced expression of small GTPases and hypermethylation of the folate binding protein gene in cisplatin-resistant cells. Br J Cancer (2004) 1.04
Assessment of disease activity in rheumatoid arthritis using a novel folate targeted radiopharmaceutical Folatescan. Clin Exp Rheumatol (2009) 1.02
Functional folate receptor alpha is elevated in the blood of ovarian cancer patients. PLoS One (2009) 0.96
Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. Clin Cancer Res (2014) 0.92
Immunotherapy for ovarian cancer. Curr Treat Options Oncol (2015) 0.89
Farletuzumab in lung cancer. Lung Cancer (2013) 0.88
The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy. Br J Cancer (2010) 0.86
Targeting folate receptor alpha for cancer treatment. Oncotarget (2016) 0.84
Distribution of OV-TL 3 and MOv18 in normal and malignant ovarian tissue. J Clin Pathol (1995) 0.82
A folic acid-based functionalized surface for biosensor systems. J Mater Sci Mater Med (2007) 0.80
Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acids. Eur J Med Chem (2015) 0.77
Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol (2008) 2.37
New classification system of radical hysterectomy: emphasis on a three-dimensional anatomic template for parametrial resection. Gynecol Oncol (2011) 2.20
Multicentre observational study of the natural history of left-sided acute diverticulitis. Br J Surg (2011) 2.16
Prospective randomized multicentre study comparing stapler haemorrhoidopexy with Doppler-guided transanal haemorrhoid dearterialization for third-degree haemorrhoids. Colorectal Dis (2012) 2.12
New grading and scoring for anal incontinence. Evaluation of 335 patients. Dis Colon Rectum (1992) 1.99
Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer (1987) 1.99
Complications after stapled hemorrhoidectomy: can they be prevented? Tech Coloproctol (2002) 1.76
Characterization of a glycosphingolipid antigen defined by the monoclonal antibody MBr1 expressed in normal and neoplastic epithelial cells of human mammary gland. J Biol Chem (1984) 1.70
Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res (1991) 1.65
Generation of monoclonal antibodies reacting with normal and cancer cells of human breast. Cancer Res (1983) 1.60
A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res (1996) 1.60
Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer (1991) 1.58
Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas. J Clin Oncol (1996) 1.55
Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors. Breast Cancer Res Treat (1999) 1.54
Intercomparison on the usage of computational codes in radiation dosimetry. Radiat Prot Dosimetry (2004) 1.51
Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro. Clin Exp Metastasis (1999) 1.46
Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity. Clin Exp Allergy (2011) 1.45
Expression of the monomeric 67-kd laminin-binding protein in human lymphomas as defined by MLuC5 monoclonal antibody and paraffin section immunohistochemistry. Hum Pathol (1995) 1.45
Role of cytokines in cancer cachexia in a murine model of intracerebral injection of human tumours. Cytokine (2001) 1.44
A preoperative single course of high-dose cisplatin and bleomycin with glutathione protection in bulky stage IB/II carcinoma of the cervix. Ann Oncol (1992) 1.42
Potentials of cell kinetics in the management of patients with ovarian cancers. Eur J Cancer (1992) 1.39
Curriculum survey on tobacco education in European dental schools. Br Dent J (2012) 1.38
Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int J Cancer (1998) 1.36
Formation of the 67-kDa laminin receptor by acylation of the precursor. J Cell Biochem (1998) 1.34
The 67-kDa laminin receptor originated from a ribosomal protein that acquired a dual function during evolution. Mol Biol Evol (1998) 1.33
Selective localization of matrix metalloproteinase 9, beta1 integrins, and human lymphocyte antigen class I molecules on membrane vesicles shed by 8701-BC breast carcinoma cells. Cancer Res (1998) 1.33
Prognostic value of alpha 6 beta 4 integrin expression in breast carcinomas is affected by laminin production from tumor cells. Clin Cancer Res (1998) 1.29
Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res (1997) 1.29
Prognostic significance of the 67-kilodalton laminin receptor expression in human breast carcinomas. J Natl Cancer Inst (1993) 1.23
Glyceryl trinitrate for chronic anal fissure--healing or headache? Results of a multicenter, randomized, placebo-controled, double-blind trial. Dis Colon Rectum (2000) 1.23
The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene (1993) 1.21
E-cadherin directly contributes to PI3K/AKT activation by engaging the PI3K-p85 regulatory subunit to adherens junctions of ovarian carcinoma cells. Oncogene (2009) 1.18
Comparison of three different methods for radiolabelling human activated T lymphocytes. Eur J Nucl Med (1997) 1.18
Immunochemical analysis of the determinant recognized by a monoclonal antibody (MBr1) which specifically binds to human mammary epithelial cells. Cancer Res (1983) 1.16
Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol (2001) 1.15
Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst (1995) 1.15
Overexpression of the 67-kD laminin receptor correlates with tumour progression in human colorectal carcinoma. J Pathol (1996) 1.13
Co-regulation and physical association of the 67-kDa monomeric laminin receptor and the alpha6beta4 integrin. J Biol Chem (1997) 1.13
The 67 kDa laminin receptor as a prognostic factor in human cancer. Breast Cancer Res Treat (1998) 1.13
Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH/3T3 cells increases cell growth in vitro and in vivo. Cancer Res (1993) 1.12
Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection. Cancer Res (1998) 1.10
Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity. Br J Cancer (1998) 1.10
Role of exon-16-deleted HER2 in breast carcinomas. Endocr Relat Cancer (2006) 1.09
Demonstration of cellular immunity against urethan-induced lung adenomas of mice. J Natl Cancer Inst (1971) 1.09
Biochemical characterization of Trop-2, a cell surface molecule expressed by human carcinomas: formal proof that the monoclonal antibodies T16 and MOv-16 recognize Trop-2. Hybridoma (1992) 1.07
Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/NEU gene amplification. Int J Cancer (1991) 1.07
Expression of protein tyrosine phosphatase alpha (RPTPalpha) in human breast cancer correlates with low tumor grade, and inhibits tumor cell growth in vitro and in vivo. Oncogene (2000) 1.07
Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer. Oncogene (2011) 1.06
In vitro demonstration of tumor-specific common antigens and embryonal antigens in murine fibrosarcomas induced by 7,12-dimethylbenz(a)anthracene. Cancer Res (1973) 1.05
Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival. Int J Cancer (1999) 1.04
Downmodulation of caveolin-1 expression in human ovarian carcinoma is directly related to alpha-folate receptor overexpression. Oncogene (2000) 1.04
Interaction of folate receptor with signaling molecules lyn and G(alpha)(i-3) in detergent-resistant complexes from the ovary carcinoma cell line IGROV1. J Cell Sci (2000) 1.04
Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis. Oncogene (1999) 1.04
Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies. Gene Ther (2003) 1.03
Factors associated with climacteric symptoms in women around menopause attending menopause clinics in Italy. Maturitas (2005) 1.03
Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation. Oncogene (1998) 1.02
Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. Cancer Res (1993) 1.02
Cellular and humoral immunity against human malignant melanoma. Int J Cancer (1971) 1.02
Generation and phenotypic characterization of new human ovarian cancer cell lines with the identification of antigens potentially recognizable by HLA-restricted cytotoxic T cells. Int J Cancer (1997) 1.02
The 67 kDa laminin receptor increases tumor aggressiveness by remodeling laminin-1. Endocr Relat Cancer (2005) 1.02
Membrane vesicles shed into the extracellular medium by human breast carcinoma cells carry tumor-associated surface antigens. Clin Exp Metastasis (1995) 0.99
Characterization of two monoclonal antibodies directed against the 67 kDa high affinity laminin receptor and application for the study of breast carcinoma progression. Clin Exp Metastasis (1992) 0.98
Cellular immunity to human breast carcinoma. Int J Cancer (1972) 0.98
Combined preoperative chemoradiotherapy followed by radical surgery in locally advanced vulvar carcinoma. A pilot study. Cancer (1996) 0.98
Simultaneous activity of two different mechanisms of folate transport in ovarian carcinoma cell lines. J Cell Biochem (1997) 0.97
Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: prognostic significance of node metastases. Gynecol Oncol (1996) 0.97
67-Kilodalton laminin receptor expression correlates with worse prognostic indicators in non-small cell lung carcinomas. Clin Cancer Res (1997) 0.96
Sequences homologous to the mouse mammary tumor virus env gene in human breast carcinoma correlate with overexpression of laminin receptor. Clin Cancer Res (1999) 0.96
Production of a monoclonal antibody directed against the recombinant SEL1L protein. Int J Biol Markers (2002) 0.96